Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) granted non-qualified stock options to purchase an aggregate of 191,000 shares of common stock to two newly hired employees on June 1, 2026.
The options, issued under the 2022 Employment Inducement Incentive Award Plan, have a $3.98 exercise price, 10-year term, and four-year vesting schedule.
Zentalis (Nasdaq: ZNTL) appointed Shannon Campbell to its Board of Directors and Sarah Kelly as Senior Vice President of Commercial Strategy.
These moves support commercialization readiness as Zentalis advances its registrational program for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, including the Phase 2 DENALI and Phase 3 ASPENOVA trials.
Zentalis (Nasdaq: ZNTL) reported Part 1 data from the Phase 1b MUIR trial of azenosertib plus paclitaxel in platinum-resistant ovarian cancer.
In 46 all-comer patients, the regimen showed 39.1% ORR, 7.3-month median PFS, and a manageable safety profile, with a 50% ORR in the 250 mg 5:2 cohort.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced management will participate in multiple investor conferences in May and June 2026, featuring fireside discussions.
Events include H.C. Wainwright, Stifel, TD Cowen, and Jefferies, with live and archived webcasts accessible via the company’s Investors & Media website section.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported first quarter 2026 results and key azenosertib milestones. The company selected 400mg QD 5:2 as the pivotal monotherapy dose in Cyclin E1-positive platinum-resistant ovarian cancer and expanded the Phase 2 DENALI trial, with topline data expected by year-end 2026.
The Phase 3 ASPENOVA confirmatory trial has dosed its first patient and plans to enroll ~420 patients. Zentalis ended Q1 2026 with $211.8 million in cash and securities, guiding runway into late 2027, and reported total operating expenses of $37.9 million.
Zentalis (Nasdaq: ZNTL) announced the first patient has been dosed in the global Phase 3 ASPENOVA trial of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. ASPENOVA is randomized and controlled to confirm benefit and support full approval while DENALI Part 2 seeks accelerated approval with a year-end 2026 topline readout.
Both trials use azenosertib 400mg QD 5:2, selected after a DENALI Part 2a interim analysis showing higher response at 400mg versus 300mg with comparable safety.
Zentalis (Nasdaq: ZNTL) announced an inducement equity grant on May 1, 2026. The Compensation Committee awarded non-qualified stock options for 26,000 shares to one newly hired employee under the 2022 Inducement Plan, with an exercise price of $4.09 per share.
The options carry a 10-year term and vest over four years: 25% at the first anniversary and the remaining 75% in equal monthly installments over the following three years, subject to continued service.
Zentalis (Nasdaq: ZNTL) announced that an abstract reporting results from Part 1 of the Phase 1b MUIR trial of azenosertib plus paclitaxel in platinum-resistant ovarian cancer (PROC) was accepted for presentation at the ASCO 2026 Annual Meeting on June 1, 2026.
The poster (Abstract 5529, Poster Board 195) will be presented during the Gynecologic Cancer poster session from 9:00–12:00 CDT and highlights combinability and activity of the regimen in an all-comer setting.
Zentalis (Nasdaq: ZNTL) will present preclinical and real-world data at AACR 2026 on azenosertib, a WEE1 inhibitor. Preclinical TNBC models showed antitumor activity (42–99% TGI) and 7/8 complete responses in an ADC-resistant PDX with azenosertib+enfortumab vedotin. Real-world ovarian cancer data show Cyclin E1-positive patients have shorter time to next treatment (13.2/14.9 vs 19.5 months; p=0.002).
The posters detail combination strategies in TNBC and unmet need in Cyclin E1-positive ovarian cancer relevant to ongoing DENALI and ASPENOVA programs.
Zentalis (Nasdaq: ZNTL) selected 400mg QD 5:2 azenosertib monotherapy as the pivotal dose for Cyclin E1-positive platinum-resistant ovarian cancer based on a prespecified DENALI Part 2a interim analysis.
The company reported a clearly differentiated response rate at 400mg versus 300mg with comparable safety, no treatment-related deaths, plans to include Part 2a data in the full Part 2 dataset, will initiate Part 2c enrollment in Q2 2026, and expects a DENALI Part 2 topline readout by year-end 2026.